
# Proton Pump Inhibitor (PPI) Pharmacokinetic Profile

## Basic Properties Comparison
| Property | Omeprazole | Esomeprazole | Lansoprazole | Pantoprazole | Rabeprazole |
|----------|------------|---------------|--------------|--------------|-------------|
| Chemical Class | Benzimidazole | S-isomer of omeprazole | Benzimidazole | Benzimidazole | Benzimidazole |
| Standard Dose | 20-40 mg | 20-40 mg | 30 mg | 40 mg | 20 mg |
| Protein Binding | 95% | 97% | 97% | 98% | 96% |
| Bioavailability | 30-40% | 64-90% | 80-85% | 77% | 52% |

## Core Pharmacokinetic Parameters
| Parameter | Omeprazole | Esomeprazole | Lansoprazole | Pantoprazole | Rabeprazole |
|-----------|------------|---------------|--------------|--------------|-------------|
| Tmax (h) | 1-4 | 1.0-3.5 | 1.2-2.1 | 2-4 | 3-5 |
| Vd (L/kg) | 0.13-0.35 | 0.22-0.26 | 0.4 | 0.15 | 0.22-0.26 |
| CL (mL/min) | 400-620 | 160-330 | 400-650 | 90-225 | 160-330 |
| t½ (h) | 0.5-1.2 | 1.3-1.6 | 0.9-2.1 | 0.8-2.0 | 0.6-1.4 |

## CYP2C19 Phenotype Effects
| Phenotype | Drug Exposure Changes |
|-----------|---------------------|
| Poor Metabolizer | 3-10× higher AUC |
| Intermediate Metabolizer | 2-3× higher AUC |
| Extensive Metabolizer | Reference |
| Ultra-rapid Metabolizer | 30-40% lower AUC |

## Pharmacodynamic Parameters
| Parameter | Value | Notes |
|-----------|--------|-------|
| Onset of Action | 2-6 h | pH >4 |
| Duration | 48-72 h | Based on pump turnover |
| pH >4 Holding Time | 6-12 h (Day 1) | Single dose |
| | 15-21 h (Day 5) | Multiple doses |

## Tissue Distribution
| Site | Concentration Ratio* |
|------|---------------------|
| Gastric Tissue | >1000:1 |
| Duodenum | 3-4:1 |
| Plasma | 1:1 |
*Tissue:Plasma ratio

## Clinical Response by CYP2C19 Status
| Parameter | PM | IM | EM | UM |
|-----------|----|----|----|----|
| Mean 24h pH | 4.5-5.5 | 4.0-5.0 | 3.5-4.5 | 3.0-4.0 |
| Time pH >4 (%) | 75-85 | 65-75 | 55-65 | 45-55 |
| H. pylori Eradication (%) | 85-95 | 75-85 | 65-75 | 55-65 |

## Drug-Drug Interactions
| Interacting Drug | Effect | Mechanism |
|-----------------|---------|------------|
| Clarithromycin | ↑ PPI levels | CYP3A4 inhibition |
| Rifampin | ↓ PPI levels | CYP induction |
| Clopidogrel | ↓ effectiveness | CYP2C19 competition |
| Ketoconazole | ↑ PPI levels | CYP3A4 inhibition |

## Pharmacokinetic/Dynamic Terms and Definitions
| Term | Definition |
|------|------------|
| AUC | Area under the plasma concentration-time curve |
| CL | Total body clearance |
| CYP | Cytochrome P450 enzyme |
| EM | Extensive metabolizer |
| IM | Intermediate metabolizer |
| PM | Poor metabolizer |
| t½ | Elimination half-life |
| Tmax | Time to maximum concentration |
| UM | Ultra-rapid metabolizer |
| Vd | Volume of distribution |

## Special Clinical Considerations
- Timing of Administration:
  - Take 30-60 minutes before meals
  - Morning dosing preferred for GERD
  - Evening dosing for nocturnal acid breakthrough
- CYP2C19 Status:
  - Consider genotyping in treatment failures
  - Dose adjustment based on metabolizer status
  - Higher doses for rapid metabolizers
- Drug Resistance Implications:
  - Limited data on antimicrobial resistance
  - Local accumulation may limit resistance development
  - High tissue:plasma ratios in gastric tissue